The quarter that just closed put the GLP-1 thesis on display in its purest form. Revenue at Eli Lilly grew nearly 48 percent year over year to about $23 billion in the three months through June. Mounjaro and Zepbound together produced roughly 65 percent of the first-half top line, and management used that cash velocity to spend more than $13 billion on acquisitions and licensing in the opening six months of the year. The defining event of the second quarter was not the sales line itself but the corporate action surrounding it. Lilly closed three separate business combinations in June and March. The company retired $4 billion of stock at a fresh all-time high in market capitalization, and increased the quarterly dividend to a record level. All of this happened while the FDA approved the new oral GLP-1 Foundayo, and the Phase 3 program for the next-generation retatrutide posted positive topline reads.
The valuation context is uncommon for a pharmaceutical company this size. Shares trade in a fifty-two week range from $712 to $1,293. The current quote sits near $1,160 and a market cap just north of $1 trillion. The trailing price-to-earnings ratio sits near 39, while the forward multiple is closer to 25. The forward figure is the more honest read because the trailing number is dragged lower by the heavy second-quarter acquired IPR&D charge. The market is paying for earnings power that the income statement does not yet show, and that gap is the core valuation debate. A target mean near $1,315 from the sell side implies single-digit upside from here, so the bear argument is that the multiple already discounts the next two years of execution.
The strongest evidence for the bull case is the durability of the volume line in the second quarter. U.S. volume grew 37 percent and ex-U.S. volume grew 113 percent, even as realized prices fell 13 percent on a consolidated basis. That is the textbook shape of a demand-led franchise rather than a price-led one, and it shows that the pricing concessions tied to the Medicare Bridge Program have not yet choked off growth. The strongest counterargument is that the manufacturing capacity build and the deal pipeline are now consuming cash at a pace that lifts debt by more than $12 billion in six months. Any stumble in tirzepatide supply or in the next retatrutide readout would compound a balance sheet that no longer has much room for absorption. The forward variables to track are retatrutide Phase 3 detail, Foundayo commercial uptake, Mounjaro pricing in China after the NRDL listing, and capital returns against the rising debt stack. The most important of these is the retatrutide readout, because it sits at the intersection of the bull and bear cases and shapes the question of whether tirzepatide is the peak or the floor of the franchise.